Assenagon Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Assenagon Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.25M	Sell	103,269 -57,346	-36%	-$1.69M	﹤0.01%	753
2026 Q1	$3.98M	Buy	160,615 +21,877	+16%	+$521K	0.01%	629
2025 Q4	$3.24M	Sell	138,738 -5,293	-4%	-$118K	﹤0.01%	743
2025 Q3	$2.84M	Buy	144,031 +39,656	+38%	+$816K	﹤0.01%	754
2025 Q2	$2.26M	Buy	104,375 +7,746	+8%	+$183K	﹤0.01%	752
2025 Q1	$2.34M	Buy	+96,629	New	+$2.18M	﹤0.01%	716

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Assenagon Asset Management's CPRX Position: Q2 2026 in Review

Assenagon Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 36% in Q2 2026, selling an estimated $1.69M and leaving 103,269 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #753.

Assenagon Asset Management first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.98M in Q1 2026. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Assenagon Asset Management held 103,269 shares of Catalyst Pharmaceutical worth $3.25M as of Q2 2026.
Assenagon Asset Management sold 57,346 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.69M.
Catalyst Pharmaceutical made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #753 holding.
Assenagon Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
Assenagon Asset Management's Catalyst Pharmaceutical position peaked at $3.98M in Q1 2026.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.